Category: Huntington's Disease
Objective: To compare the efficacy and safety of tetrabenazine, deutetrabenazine, and valbenazine for chorea and neuropsychiatric outcomes in Huntington’s disease (HD).
Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors are standard treatments for HD chorea, yet comparative data across agents remain limited. Randomized controlled trials (RCTs) of tetrabenazine, deutetrabenazine, and valbenazine provide measurable outcomes suitable for pooled evaluation.
Method: A meta‑analysis of PubMed‑indexed RCTs evaluating VMAT2 inhibitors in HD was performed. Outcomes included change in the Unified Huntington Disease Rating Scale (UHDRS)-Total Motor Chorea (TMC), Hospital Anxiety and Depression Scale (HADS), Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression–Change (CGI-C), and adverse events. Effect sizes were calculated using inverse‑variance models for continuous outcomes and Mantel‑Haenszel methods for dichotomous outcomes.
Results: Across 283 participants, VMAT2 inhibitors significantly improved UHDRS‑TMC (MD −2.97; 95% CI −3.72 to −2.21; I2 = 0%) [Figure 1]. CGI‑C response favored active treatment (RR 3.11; 95% CI 2.02–4.78) [Figure 2]. No significant worsening of depression scores was observed (SMD −0.19; 95% CI −0.43 to 0.05) [Figure 3]. Adverse‑event rates varied by agent: somnolence was more frequent with valbenazine and tetrabenazine (RR 5.11; 95% CI 1.98–13.19), while serious adverse events (RR 1.43; 95% CI 0.36–5.66), mortality (RR 0.73; 95% CI 0.09–5.81), fatigue (RR 2.16; 95% CI 1.00–4.65), akathisia (RR 2.17; 95% CI 0.61–7.64), rash (RR 3.17; 95% CI 0.88–11.34), and falls (RR 0.95; 95% CI 0.50–1.80) did not differ significantly from controls.
Conclusion: VMAT2 inhibitors provide comparable reductions in HD chorea with favorable safety and tolerability profiles. Depression scores, as measured by the HADS, showed no significant worsening. However, subtle differences in agent-specific efficacy and side effects could be better elucidated by head-to-head trials.
Figure 1
Figure 2
Figure 3
To cite this abstract in AMA style:
J. Patino, J. Pitton Rissardo, A. Fornari Caprara, A. Mcgarry, I. Walker, N. Rocha, A. Duker, E. Furr Stimming. Efficacy and Adverse Events of Tetrabenazine, Deutetrabenazine, and Valbenazine in Huntington’s Disease [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/efficacy-and-adverse-events-of-tetrabenazine-deutetrabenazine-and-valbenazine-in-huntingtons-disease/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/efficacy-and-adverse-events-of-tetrabenazine-deutetrabenazine-and-valbenazine-in-huntingtons-disease/